AGILE THERAPEUTICS INC: Nasdaq/NYSE listing notice — Agile Therapeutics receives final Nasdaq delisting notice; stock to trade on OTC Markets from March 26

AGILE THERAPEUTICS INC

Delisting due to failure to maintain minimum stockholders' equity of $2.5M per Nasdaq Listing Rule 5550(b)(1).
Trading suspended on Nasdaq at open March 26, 2024; common stock to trade on OTC Markets under symbol AGRX.
Company does not plan to appeal the Nasdaq Hearings Panel's determination.
Company expects to continue operations and explore strategic opportunities to maximize Twirla growth.
Common stock will remain registered under the Exchange Act; company will continue SEC filings.

item 3.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

AGILE THERAPEUTICS INC received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

disclosed, on March 27, 2023, the Company received a letter from the Nasdaq Listing Qualifications Department (the “Staff”) indicating that it was not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(b)(1) requiring companies listed on the Nasdaq Capital Market to maintain stockholder’s equity of at least $2,500,000 (the “Rule”). On June 2, 2023, based on the Staff’s review of the materials submitted by the Company, the Staff granted the Company’s request for an extension until September 25

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001558370-24-003854

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.